nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—ALB—Vandetanib—thyroid cancer	0.302	0.755	CbGbCtD
Valsartan—CYP2C9—Sorafenib—thyroid cancer	0.0981	0.245	CbGbCtD
Valsartan—Anxiety—Vandetanib—thyroid cancer	0.0032	0.00543	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00319	0.00541	CcSEcCtD
Valsartan—Dry mouth—Vandetanib—thyroid cancer	0.00314	0.00533	CcSEcCtD
Valsartan—Oedema—Vandetanib—thyroid cancer	0.00308	0.00522	CcSEcCtD
Valsartan—Epistaxis—Sorafenib—thyroid cancer	0.00307	0.00521	CcSEcCtD
Valsartan—Infection—Vandetanib—thyroid cancer	0.00306	0.00519	CcSEcCtD
Valsartan—Nervous system disorder—Vandetanib—thyroid cancer	0.00302	0.00512	CcSEcCtD
Valsartan—Thrombocytopenia—Vandetanib—thyroid cancer	0.00302	0.00511	CcSEcCtD
Valsartan—Skin disorder—Vandetanib—thyroid cancer	0.00299	0.00507	CcSEcCtD
Valsartan—Haemoglobin—Sorafenib—thyroid cancer	0.00294	0.00498	CcSEcCtD
Valsartan—Haemorrhage—Sorafenib—thyroid cancer	0.00292	0.00496	CcSEcCtD
Valsartan—Urinary tract disorder—Sorafenib—thyroid cancer	0.00289	0.0049	CcSEcCtD
Valsartan—Connective tissue disorder—Sorafenib—thyroid cancer	0.00287	0.00487	CcSEcCtD
Valsartan—Urethral disorder—Sorafenib—thyroid cancer	0.00287	0.00486	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00281	0.00476	CcSEcCtD
Valsartan—Insomnia—Vandetanib—thyroid cancer	0.00279	0.00472	CcSEcCtD
Valsartan—Paraesthesia—Vandetanib—thyroid cancer	0.00277	0.00469	CcSEcCtD
Valsartan—Dyspnoea—Vandetanib—thyroid cancer	0.00275	0.00465	CcSEcCtD
Valsartan—Cardiac disorder—Sorafenib—thyroid cancer	0.00271	0.0046	CcSEcCtD
Valsartan—Dyspepsia—Vandetanib—thyroid cancer	0.00271	0.0046	CcSEcCtD
Valsartan—Decreased appetite—Vandetanib—thyroid cancer	0.00268	0.00454	CcSEcCtD
Valsartan—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00266	0.00451	CcSEcCtD
Valsartan—Ageusia—Epirubicin—thyroid cancer	0.00266	0.0045	CcSEcCtD
Valsartan—Fatigue—Vandetanib—thyroid cancer	0.00265	0.0045	CcSEcCtD
Valsartan—Angiopathy—Sorafenib—thyroid cancer	0.00265	0.0045	CcSEcCtD
Valsartan—Immune system disorder—Sorafenib—thyroid cancer	0.00264	0.00448	CcSEcCtD
Valsartan—Mediastinal disorder—Sorafenib—thyroid cancer	0.00264	0.00447	CcSEcCtD
Valsartan—Constipation—Vandetanib—thyroid cancer	0.00263	0.00446	CcSEcCtD
Valsartan—Alopecia—Sorafenib—thyroid cancer	0.00258	0.00438	CcSEcCtD
Valsartan—Mental disorder—Sorafenib—thyroid cancer	0.00256	0.00434	CcSEcCtD
Valsartan—Malnutrition—Sorafenib—thyroid cancer	0.00255	0.00432	CcSEcCtD
Valsartan—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00252	0.00427	CcSEcCtD
Valsartan—Dysgeusia—Sorafenib—thyroid cancer	0.00249	0.00423	CcSEcCtD
Valsartan—Ageusia—Doxorubicin—thyroid cancer	0.00246	0.00417	CcSEcCtD
Valsartan—Muscle spasms—Sorafenib—thyroid cancer	0.00245	0.00415	CcSEcCtD
Valsartan—Abdominal pain—Vandetanib—thyroid cancer	0.00243	0.00413	CcSEcCtD
Valsartan—Viral infection—Epirubicin—thyroid cancer	0.00238	0.00404	CcSEcCtD
Valsartan—Angioedema—Sorafenib—thyroid cancer	0.00233	0.00394	CcSEcCtD
Valsartan—Syncope—Sorafenib—thyroid cancer	0.00228	0.00387	CcSEcCtD
Valsartan—Loss of consciousness—Sorafenib—thyroid cancer	0.00224	0.00379	CcSEcCtD
Valsartan—Cough—Sorafenib—thyroid cancer	0.00222	0.00377	CcSEcCtD
Valsartan—Asthenia—Vandetanib—thyroid cancer	0.00221	0.00375	CcSEcCtD
Valsartan—Viral infection—Doxorubicin—thyroid cancer	0.0022	0.00374	CcSEcCtD
Valsartan—Pruritus—Vandetanib—thyroid cancer	0.00218	0.00369	CcSEcCtD
Valsartan—Myalgia—Sorafenib—thyroid cancer	0.00217	0.00367	CcSEcCtD
Valsartan—Arthralgia—Sorafenib—thyroid cancer	0.00217	0.00367	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00215	0.00365	CcSEcCtD
Valsartan—Dry mouth—Sorafenib—thyroid cancer	0.00212	0.00359	CcSEcCtD
Valsartan—Hyperkalaemia—Epirubicin—thyroid cancer	0.00211	0.00358	CcSEcCtD
Valsartan—Diarrhoea—Vandetanib—thyroid cancer	0.00211	0.00357	CcSEcCtD
Valsartan—Anaphylactic shock—Sorafenib—thyroid cancer	0.00208	0.00352	CcSEcCtD
Valsartan—Infection—Sorafenib—thyroid cancer	0.00206	0.0035	CcSEcCtD
Valsartan—Shock—Sorafenib—thyroid cancer	0.00204	0.00346	CcSEcCtD
Valsartan—Nervous system disorder—Sorafenib—thyroid cancer	0.00204	0.00345	CcSEcCtD
Valsartan—Dizziness—Vandetanib—thyroid cancer	0.00204	0.00345	CcSEcCtD
Valsartan—Thrombocytopenia—Sorafenib—thyroid cancer	0.00203	0.00345	CcSEcCtD
Valsartan—Blood urea increased—Epirubicin—thyroid cancer	0.00203	0.00344	CcSEcCtD
Valsartan—Skin disorder—Sorafenib—thyroid cancer	0.00202	0.00342	CcSEcCtD
Valsartan—Anorexia—Sorafenib—thyroid cancer	0.00198	0.00336	CcSEcCtD
Valsartan—Vomiting—Vandetanib—thyroid cancer	0.00196	0.00332	CcSEcCtD
Valsartan—Hyperkalaemia—Doxorubicin—thyroid cancer	0.00196	0.00332	CcSEcCtD
Valsartan—Rash—Vandetanib—thyroid cancer	0.00194	0.00329	CcSEcCtD
Valsartan—Dermatitis—Vandetanib—thyroid cancer	0.00194	0.00329	CcSEcCtD
Valsartan—Headache—Vandetanib—thyroid cancer	0.00193	0.00327	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00189	0.00321	CcSEcCtD
Valsartan—Blood urea increased—Doxorubicin—thyroid cancer	0.00188	0.00319	CcSEcCtD
Valsartan—Dyspnoea—Sorafenib—thyroid cancer	0.00185	0.00314	CcSEcCtD
Valsartan—Nausea—Vandetanib—thyroid cancer	0.00183	0.0031	CcSEcCtD
Valsartan—Dyspepsia—Sorafenib—thyroid cancer	0.00183	0.0031	CcSEcCtD
Valsartan—Decreased appetite—Sorafenib—thyroid cancer	0.00181	0.00306	CcSEcCtD
Valsartan—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00179	0.00304	CcSEcCtD
Valsartan—Fatigue—Sorafenib—thyroid cancer	0.00179	0.00304	CcSEcCtD
Valsartan—Photosensitivity—Epirubicin—thyroid cancer	0.00178	0.00302	CcSEcCtD
Valsartan—Constipation—Sorafenib—thyroid cancer	0.00178	0.00301	CcSEcCtD
Valsartan—Gastrointestinal pain—Sorafenib—thyroid cancer	0.0017	0.00288	CcSEcCtD
Valsartan—Renal failure acute—Epirubicin—thyroid cancer	0.00169	0.00287	CcSEcCtD
Valsartan—Urticaria—Sorafenib—thyroid cancer	0.00165	0.0028	CcSEcCtD
Valsartan—Photosensitivity—Doxorubicin—thyroid cancer	0.00165	0.00279	CcSEcCtD
Valsartan—Abdominal pain—Sorafenib—thyroid cancer	0.00164	0.00278	CcSEcCtD
Valsartan—Renal impairment—Epirubicin—thyroid cancer	0.00164	0.00278	CcSEcCtD
Valsartan—Dermatitis bullous—Epirubicin—thyroid cancer	0.00163	0.00277	CcSEcCtD
Valsartan—Cardiac failure—Epirubicin—thyroid cancer	0.0016	0.00271	CcSEcCtD
Valsartan—Hyponatraemia—Epirubicin—thyroid cancer	0.00157	0.00266	CcSEcCtD
Valsartan—Renal failure acute—Doxorubicin—thyroid cancer	0.00157	0.00265	CcSEcCtD
Valsartan—Hypersensitivity—Sorafenib—thyroid cancer	0.00153	0.00259	CcSEcCtD
Valsartan—Renal impairment—Doxorubicin—thyroid cancer	0.00152	0.00257	CcSEcCtD
Valsartan—Dermatitis bullous—Doxorubicin—thyroid cancer	0.00151	0.00256	CcSEcCtD
Valsartan—Asthenia—Sorafenib—thyroid cancer	0.00149	0.00253	CcSEcCtD
Valsartan—Cardiac failure—Doxorubicin—thyroid cancer	0.00148	0.00251	CcSEcCtD
Valsartan—Pruritus—Sorafenib—thyroid cancer	0.00147	0.00249	CcSEcCtD
Valsartan—Blood creatinine increased—Epirubicin—thyroid cancer	0.00146	0.00248	CcSEcCtD
Valsartan—Hyponatraemia—Doxorubicin—thyroid cancer	0.00145	0.00246	CcSEcCtD
Valsartan—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00143	0.00242	CcSEcCtD
Valsartan—Abdominal pain upper—Epirubicin—thyroid cancer	0.00143	0.00242	CcSEcCtD
Valsartan—Diarrhoea—Sorafenib—thyroid cancer	0.00142	0.00241	CcSEcCtD
Valsartan—Muscular weakness—Epirubicin—thyroid cancer	0.00138	0.00234	CcSEcCtD
Valsartan—Dizziness—Sorafenib—thyroid cancer	0.00137	0.00233	CcSEcCtD
Valsartan—Blood creatinine increased—Doxorubicin—thyroid cancer	0.00135	0.0023	CcSEcCtD
Valsartan—Vomiting—Sorafenib—thyroid cancer	0.00132	0.00224	CcSEcCtD
Valsartan—Abdominal pain upper—Doxorubicin—thyroid cancer	0.00132	0.00224	CcSEcCtD
Valsartan—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.00132	0.00224	CcSEcCtD
Valsartan—Rash—Sorafenib—thyroid cancer	0.00131	0.00222	CcSEcCtD
Valsartan—Dermatitis—Sorafenib—thyroid cancer	0.00131	0.00222	CcSEcCtD
Valsartan—Headache—Sorafenib—thyroid cancer	0.0013	0.00221	CcSEcCtD
Valsartan—Bronchitis—Epirubicin—thyroid cancer	0.0013	0.0022	CcSEcCtD
Valsartan—Muscular weakness—Doxorubicin—thyroid cancer	0.00127	0.00216	CcSEcCtD
Valsartan—Neutropenia—Epirubicin—thyroid cancer	0.00126	0.00214	CcSEcCtD
Valsartan—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.00125	0.00213	CcSEcCtD
Valsartan—Nausea—Sorafenib—thyroid cancer	0.00123	0.00209	CcSEcCtD
Valsartan—Photosensitivity reaction—Epirubicin—thyroid cancer	0.00123	0.00209	CcSEcCtD
Valsartan—Infestation—Epirubicin—thyroid cancer	0.0012	0.00204	CcSEcCtD
Valsartan—Infestation NOS—Epirubicin—thyroid cancer	0.0012	0.00204	CcSEcCtD
Valsartan—Bronchitis—Doxorubicin—thyroid cancer	0.0012	0.00204	CcSEcCtD
Valsartan—Renal failure—Epirubicin—thyroid cancer	0.00118	0.00201	CcSEcCtD
Valsartan—Neutropenia—Doxorubicin—thyroid cancer	0.00117	0.00198	CcSEcCtD
Valsartan—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.00116	0.00197	CcSEcCtD
Valsartan—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.00114	0.00193	CcSEcCtD
Valsartan—Epistaxis—Epirubicin—thyroid cancer	0.00114	0.00192	CcSEcCtD
Valsartan—Sinusitis—Epirubicin—thyroid cancer	0.00113	0.00191	CcSEcCtD
Valsartan—Infestation—Doxorubicin—thyroid cancer	0.00111	0.00189	CcSEcCtD
Valsartan—Infestation NOS—Doxorubicin—thyroid cancer	0.00111	0.00189	CcSEcCtD
Valsartan—Renal failure—Doxorubicin—thyroid cancer	0.00109	0.00186	CcSEcCtD
Valsartan—Haemoglobin—Epirubicin—thyroid cancer	0.00109	0.00184	CcSEcCtD
Valsartan—Rhinitis—Epirubicin—thyroid cancer	0.00108	0.00184	CcSEcCtD
Valsartan—Haemorrhage—Epirubicin—thyroid cancer	0.00108	0.00183	CcSEcCtD
Valsartan—Hepatitis—Epirubicin—thyroid cancer	0.00108	0.00183	CcSEcCtD
Valsartan—Pharyngitis—Epirubicin—thyroid cancer	0.00107	0.00182	CcSEcCtD
Valsartan—Urinary tract disorder—Epirubicin—thyroid cancer	0.00107	0.00181	CcSEcCtD
Valsartan—Connective tissue disorder—Epirubicin—thyroid cancer	0.00106	0.0018	CcSEcCtD
Valsartan—Urethral disorder—Epirubicin—thyroid cancer	0.00106	0.0018	CcSEcCtD
Valsartan—Epistaxis—Doxorubicin—thyroid cancer	0.00105	0.00178	CcSEcCtD
Valsartan—Sinusitis—Doxorubicin—thyroid cancer	0.00104	0.00177	CcSEcCtD
Valsartan—Haemoglobin—Doxorubicin—thyroid cancer	0.001	0.0017	CcSEcCtD
Valsartan—Cardiac disorder—Epirubicin—thyroid cancer	0.001	0.0017	CcSEcCtD
Valsartan—Rhinitis—Doxorubicin—thyroid cancer	0.001	0.0017	CcSEcCtD
Valsartan—Haemorrhage—Doxorubicin—thyroid cancer	0.001	0.0017	CcSEcCtD
Valsartan—Hepatitis—Doxorubicin—thyroid cancer	0.001	0.0017	CcSEcCtD
Valsartan—Pharyngitis—Doxorubicin—thyroid cancer	0.000992	0.00168	CcSEcCtD
Valsartan—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000987	0.00167	CcSEcCtD
Valsartan—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000982	0.00167	CcSEcCtD
Valsartan—Angiopathy—Epirubicin—thyroid cancer	0.00098	0.00166	CcSEcCtD
Valsartan—Urethral disorder—Doxorubicin—thyroid cancer	0.00098	0.00166	CcSEcCtD
Valsartan—Immune system disorder—Epirubicin—thyroid cancer	0.000976	0.00165	CcSEcCtD
Valsartan—Mediastinal disorder—Epirubicin—thyroid cancer	0.000974	0.00165	CcSEcCtD
Valsartan—Alopecia—Epirubicin—thyroid cancer	0.000955	0.00162	CcSEcCtD
Valsartan—Mental disorder—Epirubicin—thyroid cancer	0.000947	0.0016	CcSEcCtD
Valsartan—Malnutrition—Epirubicin—thyroid cancer	0.000941	0.00159	CcSEcCtD
Valsartan—Cardiac disorder—Doxorubicin—thyroid cancer	0.000928	0.00157	CcSEcCtD
Valsartan—Flatulence—Epirubicin—thyroid cancer	0.000927	0.00157	CcSEcCtD
Valsartan—Dysgeusia—Epirubicin—thyroid cancer	0.000921	0.00156	CcSEcCtD
Valsartan—Back pain—Epirubicin—thyroid cancer	0.00091	0.00154	CcSEcCtD
Valsartan—Angiopathy—Doxorubicin—thyroid cancer	0.000907	0.00154	CcSEcCtD
Valsartan—Muscle spasms—Epirubicin—thyroid cancer	0.000904	0.00153	CcSEcCtD
Valsartan—Immune system disorder—Doxorubicin—thyroid cancer	0.000903	0.00153	CcSEcCtD
Valsartan—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000901	0.00153	CcSEcCtD
Valsartan—Vision blurred—Epirubicin—thyroid cancer	0.000886	0.0015	CcSEcCtD
Valsartan—Alopecia—Doxorubicin—thyroid cancer	0.000883	0.0015	CcSEcCtD
Valsartan—Mental disorder—Doxorubicin—thyroid cancer	0.000876	0.00149	CcSEcCtD
Valsartan—Malnutrition—Doxorubicin—thyroid cancer	0.00087	0.00148	CcSEcCtD
Valsartan—Flatulence—Doxorubicin—thyroid cancer	0.000858	0.00145	CcSEcCtD
Valsartan—Dysgeusia—Doxorubicin—thyroid cancer	0.000852	0.00144	CcSEcCtD
Valsartan—Vertigo—Epirubicin—thyroid cancer	0.000845	0.00143	CcSEcCtD
Valsartan—Syncope—Epirubicin—thyroid cancer	0.000844	0.00143	CcSEcCtD
Valsartan—Back pain—Doxorubicin—thyroid cancer	0.000842	0.00143	CcSEcCtD
Valsartan—Muscle spasms—Doxorubicin—thyroid cancer	0.000837	0.00142	CcSEcCtD
Valsartan—Palpitations—Epirubicin—thyroid cancer	0.000831	0.00141	CcSEcCtD
Valsartan—Loss of consciousness—Epirubicin—thyroid cancer	0.000827	0.0014	CcSEcCtD
Valsartan—Cough—Epirubicin—thyroid cancer	0.000821	0.00139	CcSEcCtD
Valsartan—Vision blurred—Doxorubicin—thyroid cancer	0.00082	0.00139	CcSEcCtD
Valsartan—Arthralgia—Epirubicin—thyroid cancer	0.000801	0.00136	CcSEcCtD
Valsartan—Chest pain—Epirubicin—thyroid cancer	0.000801	0.00136	CcSEcCtD
Valsartan—Myalgia—Epirubicin—thyroid cancer	0.000801	0.00136	CcSEcCtD
Valsartan—Anxiety—Epirubicin—thyroid cancer	0.000798	0.00135	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000795	0.00135	CcSEcCtD
Valsartan—Dry mouth—Epirubicin—thyroid cancer	0.000783	0.00133	CcSEcCtD
Valsartan—Vertigo—Doxorubicin—thyroid cancer	0.000782	0.00133	CcSEcCtD
Valsartan—Syncope—Doxorubicin—thyroid cancer	0.000781	0.00132	CcSEcCtD
Valsartan—Palpitations—Doxorubicin—thyroid cancer	0.000769	0.0013	CcSEcCtD
Valsartan—Anaphylactic shock—Epirubicin—thyroid cancer	0.000768	0.0013	CcSEcCtD
Valsartan—Oedema—Epirubicin—thyroid cancer	0.000768	0.0013	CcSEcCtD
Valsartan—Loss of consciousness—Doxorubicin—thyroid cancer	0.000765	0.0013	CcSEcCtD
Valsartan—Infection—Epirubicin—thyroid cancer	0.000763	0.00129	CcSEcCtD
Valsartan—Cough—Doxorubicin—thyroid cancer	0.000759	0.00129	CcSEcCtD
Valsartan—Shock—Epirubicin—thyroid cancer	0.000755	0.00128	CcSEcCtD
Valsartan—Nervous system disorder—Epirubicin—thyroid cancer	0.000753	0.00128	CcSEcCtD
Valsartan—Thrombocytopenia—Epirubicin—thyroid cancer	0.000752	0.00127	CcSEcCtD
Valsartan—Skin disorder—Epirubicin—thyroid cancer	0.000746	0.00126	CcSEcCtD
Valsartan—Chest pain—Doxorubicin—thyroid cancer	0.000741	0.00126	CcSEcCtD
Valsartan—Arthralgia—Doxorubicin—thyroid cancer	0.000741	0.00126	CcSEcCtD
Valsartan—Myalgia—Doxorubicin—thyroid cancer	0.000741	0.00126	CcSEcCtD
Valsartan—Anxiety—Doxorubicin—thyroid cancer	0.000738	0.00125	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000736	0.00125	CcSEcCtD
Valsartan—Anorexia—Epirubicin—thyroid cancer	0.000732	0.00124	CcSEcCtD
Valsartan—SLCO1B3—Recycling of bile acids and salts—RXRA—thyroid cancer	0.000727	0.0713	CbGpPWpGaD
Valsartan—Dry mouth—Doxorubicin—thyroid cancer	0.000725	0.00123	CcSEcCtD
Valsartan—Hypotension—Epirubicin—thyroid cancer	0.000717	0.00122	CcSEcCtD
Valsartan—Oedema—Doxorubicin—thyroid cancer	0.00071	0.0012	CcSEcCtD
Valsartan—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00071	0.0012	CcSEcCtD
Valsartan—AGTR1—Arf6 signaling events—TSHR—thyroid cancer	0.000708	0.0695	CbGpPWpGaD
Valsartan—Infection—Doxorubicin—thyroid cancer	0.000706	0.0012	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000699	0.00119	CcSEcCtD
Valsartan—Shock—Doxorubicin—thyroid cancer	0.000699	0.00118	CcSEcCtD
Valsartan—Nervous system disorder—Doxorubicin—thyroid cancer	0.000697	0.00118	CcSEcCtD
Valsartan—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000695	0.00118	CcSEcCtD
Valsartan—Insomnia—Epirubicin—thyroid cancer	0.000694	0.00118	CcSEcCtD
Valsartan—Skin disorder—Doxorubicin—thyroid cancer	0.00069	0.00117	CcSEcCtD
Valsartan—Paraesthesia—Epirubicin—thyroid cancer	0.000689	0.00117	CcSEcCtD
Valsartan—Dyspnoea—Epirubicin—thyroid cancer	0.000684	0.00116	CcSEcCtD
Valsartan—Somnolence—Epirubicin—thyroid cancer	0.000682	0.00116	CcSEcCtD
Valsartan—Anorexia—Doxorubicin—thyroid cancer	0.000677	0.00115	CcSEcCtD
Valsartan—Dyspepsia—Epirubicin—thyroid cancer	0.000676	0.00115	CcSEcCtD
Valsartan—Decreased appetite—Epirubicin—thyroid cancer	0.000667	0.00113	CcSEcCtD
Valsartan—Hypotension—Doxorubicin—thyroid cancer	0.000664	0.00113	CcSEcCtD
Valsartan—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000663	0.00112	CcSEcCtD
Valsartan—Fatigue—Epirubicin—thyroid cancer	0.000662	0.00112	CcSEcCtD
Valsartan—Constipation—Epirubicin—thyroid cancer	0.000656	0.00111	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000647	0.0011	CcSEcCtD
Valsartan—Insomnia—Doxorubicin—thyroid cancer	0.000642	0.00109	CcSEcCtD
Valsartan—Paraesthesia—Doxorubicin—thyroid cancer	0.000638	0.00108	CcSEcCtD
Valsartan—Dyspnoea—Doxorubicin—thyroid cancer	0.000633	0.00107	CcSEcCtD
Valsartan—Somnolence—Doxorubicin—thyroid cancer	0.000631	0.00107	CcSEcCtD
Valsartan—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000628	0.00106	CcSEcCtD
Valsartan—Dyspepsia—Doxorubicin—thyroid cancer	0.000625	0.00106	CcSEcCtD
Valsartan—Decreased appetite—Doxorubicin—thyroid cancer	0.000617	0.00105	CcSEcCtD
Valsartan—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000613	0.00104	CcSEcCtD
Valsartan—Fatigue—Doxorubicin—thyroid cancer	0.000612	0.00104	CcSEcCtD
Valsartan—Urticaria—Epirubicin—thyroid cancer	0.00061	0.00103	CcSEcCtD
Valsartan—Constipation—Doxorubicin—thyroid cancer	0.000607	0.00103	CcSEcCtD
Valsartan—Abdominal pain—Epirubicin—thyroid cancer	0.000607	0.00103	CcSEcCtD
Valsartan—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000581	0.000985	CcSEcCtD
Valsartan—Hypersensitivity—Epirubicin—thyroid cancer	0.000566	0.000959	CcSEcCtD
Valsartan—Urticaria—Doxorubicin—thyroid cancer	0.000564	0.000957	CcSEcCtD
Valsartan—Abdominal pain—Doxorubicin—thyroid cancer	0.000562	0.000952	CcSEcCtD
Valsartan—AGTR1—Arf6 trafficking events—TSHR—thyroid cancer	0.00056	0.0549	CbGpPWpGaD
Valsartan—Asthenia—Epirubicin—thyroid cancer	0.000551	0.000934	CcSEcCtD
Valsartan—Pruritus—Epirubicin—thyroid cancer	0.000543	0.000921	CcSEcCtD
Valsartan—Diarrhoea—Epirubicin—thyroid cancer	0.000525	0.000891	CcSEcCtD
Valsartan—Hypersensitivity—Doxorubicin—thyroid cancer	0.000523	0.000887	CcSEcCtD
Valsartan—Asthenia—Doxorubicin—thyroid cancer	0.00051	0.000864	CcSEcCtD
Valsartan—Dizziness—Epirubicin—thyroid cancer	0.000508	0.000861	CcSEcCtD
Valsartan—Pruritus—Doxorubicin—thyroid cancer	0.000503	0.000852	CcSEcCtD
Valsartan—SLCO1B1—Recycling of bile acids and salts—RXRA—thyroid cancer	0.000489	0.0479	CbGpPWpGaD
Valsartan—Vomiting—Epirubicin—thyroid cancer	0.000488	0.000828	CcSEcCtD
Valsartan—Diarrhoea—Doxorubicin—thyroid cancer	0.000486	0.000824	CcSEcCtD
Valsartan—Rash—Epirubicin—thyroid cancer	0.000484	0.000821	CcSEcCtD
Valsartan—Dermatitis—Epirubicin—thyroid cancer	0.000484	0.00082	CcSEcCtD
Valsartan—Headache—Epirubicin—thyroid cancer	0.000481	0.000815	CcSEcCtD
Valsartan—Dizziness—Doxorubicin—thyroid cancer	0.00047	0.000796	CcSEcCtD
Valsartan—Nausea—Epirubicin—thyroid cancer	0.000456	0.000773	CcSEcCtD
Valsartan—Vomiting—Doxorubicin—thyroid cancer	0.000452	0.000766	CcSEcCtD
Valsartan—Rash—Doxorubicin—thyroid cancer	0.000448	0.000759	CcSEcCtD
Valsartan—Dermatitis—Doxorubicin—thyroid cancer	0.000447	0.000759	CcSEcCtD
Valsartan—Headache—Doxorubicin—thyroid cancer	0.000445	0.000754	CcSEcCtD
Valsartan—Nausea—Doxorubicin—thyroid cancer	0.000422	0.000715	CcSEcCtD
Valsartan—AGTR1—Peptide GPCRs—TSHR—thyroid cancer	0.000389	0.0382	CbGpPWpGaD
Valsartan—SLCO1B3—Bile acid and bile salt metabolism—RXRA—thyroid cancer	0.00038	0.0373	CbGpPWpGaD
Valsartan—ALB—FOXA2 and FOXA3 transcription factor networks—NKX2-1—thyroid cancer	0.000307	0.0301	CbGpPWpGaD
Valsartan—ALB—Recycling of bile acids and salts—RXRA—thyroid cancer	0.000279	0.0274	CbGpPWpGaD
Valsartan—SLCO1B1—Bile acid and bile salt metabolism—RXRA—thyroid cancer	0.000255	0.0251	CbGpPWpGaD
Valsartan—CYP2C9—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000254	0.0249	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CALCB—thyroid cancer	0.000202	0.0198	CbGpPWpGaD
Valsartan—ALB—Bile acid and bile salt metabolism—RXRA—thyroid cancer	0.000146	0.0143	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—SST—thyroid cancer	0.000142	0.014	CbGpPWpGaD
Valsartan—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000131	0.0129	CbGpPWpGaD
Valsartan—SLCO1B3—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000124	0.0122	CbGpPWpGaD
Valsartan—SLCO1B3—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000124	0.0122	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000123	0.012	CbGpPWpGaD
Valsartan—CYP2C9—Metapathway biotransformation—CHST14—thyroid cancer	0.000116	0.0114	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000116	0.0113	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CALCB—thyroid cancer	0.000114	0.0112	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.000112	0.011	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CALCB—thyroid cancer	0.000104	0.0102	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	9.55e-05	0.00937	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—TSHR—thyroid cancer	9.35e-05	0.00917	CbGpPWpGaD
Valsartan—SLCO1B3—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	9.3e-05	0.00912	CbGpPWpGaD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—AKT1—thyroid cancer	8.36e-05	0.0082	CbGpPWpGaD
Valsartan—SLCO1B1—SLC-mediated transmembrane transport—TPR—thyroid cancer	8.35e-05	0.00819	CbGpPWpGaD
Valsartan—SLCO1B1—SLC-mediated transmembrane transport—CP—thyroid cancer	8.35e-05	0.00819	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—MINPP1—thyroid cancer	7.99e-05	0.00784	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—PTCH1—thyroid cancer	7.95e-05	0.0078	CbGpPWpGaD
Valsartan—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	7.94e-05	0.00779	CbGpPWpGaD
Valsartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	7.89e-05	0.00774	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	7.77e-05	0.00762	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—SST—thyroid cancer	7.27e-05	0.00713	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CALCA—thyroid cancer	7e-05	0.00686	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—NDUFA13—thyroid cancer	6.8e-05	0.00666	CbGpPWpGaD
Valsartan—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	6.43e-05	0.00631	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CHST14—thyroid cancer	6.39e-05	0.00627	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—TPR—thyroid cancer	6.31e-05	0.00619	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—CP—thyroid cancer	6.31e-05	0.00619	CbGpPWpGaD
Valsartan—SLCO1B1—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	6.25e-05	0.00613	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	6.21e-05	0.00609	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CALCB—thyroid cancer	6.12e-05	0.00601	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TRIM33—thyroid cancer	5.8e-05	0.00569	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—MINPP1—thyroid cancer	5.37e-05	0.00527	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—TSHR—thyroid cancer	5.28e-05	0.00518	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—HPGD—thyroid cancer	5.15e-05	0.00505	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—TSHR—thyroid cancer	4.8e-05	0.00471	CbGpPWpGaD
Valsartan—ALB—SLC-mediated transmembrane transport—TPR—thyroid cancer	4.77e-05	0.00468	CbGpPWpGaD
Valsartan—ALB—SLC-mediated transmembrane transport—CP—thyroid cancer	4.77e-05	0.00468	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	4.73e-05	0.00464	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PRKAR1A—thyroid cancer	4.72e-05	0.00463	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NDUFA13—thyroid cancer	4.57e-05	0.00448	CbGpPWpGaD
Valsartan—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	4.56e-05	0.00447	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	4.44e-05	0.00435	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CHST14—thyroid cancer	4.29e-05	0.00421	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—CP—thyroid cancer	4.24e-05	0.00416	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—TPR—thyroid cancer	4.24e-05	0.00416	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.18e-05	0.0041	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	4.17e-05	0.00409	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—SST—thyroid cancer	4.11e-05	0.00403	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PTCH1—thyroid cancer	4.08e-05	0.004	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	4.03e-05	0.00395	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—RXRA—thyroid cancer	3.97e-05	0.0039	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CALCA—thyroid cancer	3.96e-05	0.00388	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TCF7L1—thyroid cancer	3.87e-05	0.0038	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—SST—thyroid cancer	3.73e-05	0.00366	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	3.63e-05	0.00356	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CALCA—thyroid cancer	3.59e-05	0.00352	CbGpPWpGaD
Valsartan—ALB—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	3.57e-05	0.0035	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—PTGS2—thyroid cancer	3.55e-05	0.00348	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	3.47e-05	0.0034	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—HPGD—thyroid cancer	3.46e-05	0.00339	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—RXRA—thyroid cancer	3.42e-05	0.00335	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CDK1—thyroid cancer	3.25e-05	0.00319	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	3.18e-05	0.00312	CbGpPWpGaD
Valsartan—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	3.1e-05	0.00304	CbGpPWpGaD
Valsartan—ALB—Metabolism—MINPP1—thyroid cancer	3.07e-05	0.00301	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—TPR—thyroid cancer	2.96e-05	0.0029	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	2.95e-05	0.00289	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PRKAR1A—thyroid cancer	2.91e-05	0.00285	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TSHR—thyroid cancer	2.83e-05	0.00278	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.81e-05	0.00275	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PRKAR1A—thyroid cancer	2.79e-05	0.00274	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PRKAR1A—thyroid cancer	2.76e-05	0.0027	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—RXRA—thyroid cancer	2.67e-05	0.00262	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MEN1—thyroid cancer	2.66e-05	0.00261	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—TP53—thyroid cancer	2.66e-05	0.00261	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.64e-05	0.00259	CbGpPWpGaD
Valsartan—ALB—Metabolism—NDUFA13—thyroid cancer	2.61e-05	0.00256	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—MINPP1—thyroid cancer	2.51e-05	0.00246	CbGpPWpGaD
Valsartan—ALB—Metabolism—CHST14—thyroid cancer	2.45e-05	0.00241	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—TPR—thyroid cancer	2.42e-05	0.00238	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—CP—thyroid cancer	2.42e-05	0.00238	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PTCH1—thyroid cancer	2.41e-05	0.00236	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	2.38e-05	0.00234	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—SLC5A5—thyroid cancer	2.21e-05	0.00217	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SST—thyroid cancer	2.2e-05	0.00216	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NDUFA13—thyroid cancer	2.14e-05	0.00209	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CALCA—thyroid cancer	2.12e-05	0.00208	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.07e-05	0.00204	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CHST14—thyroid cancer	2.01e-05	0.00197	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—TPR—thyroid cancer	1.99e-05	0.00195	CbGpPWpGaD
Valsartan—ALB—Metabolism—HPGD—thyroid cancer	1.98e-05	0.00194	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PRKAR1A—thyroid cancer	1.96e-05	0.00192	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CDK1—thyroid cancer	1.92e-05	0.00188	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—RXRA—thyroid cancer	1.86e-05	0.00182	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IFNA2—thyroid cancer	1.83e-05	0.00179	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	1.81e-05	0.00178	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.81e-05	0.00177	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.77e-05	0.00174	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HPGD—thyroid cancer	1.62e-05	0.00159	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	1.6e-05	0.00157	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NRG1—thyroid cancer	1.54e-05	0.00151	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—RXRA—thyroid cancer	1.52e-05	0.0015	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—SLC5A5—thyroid cancer	1.49e-05	0.00146	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.39e-05	0.00137	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TERT—thyroid cancer	1.38e-05	0.00136	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HIF1A—thyroid cancer	1.32e-05	0.0013	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	1.31e-05	0.00129	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—RXRA—thyroid cancer	1.25e-05	0.00123	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.22e-05	0.00119	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PPARG—thyroid cancer	1.17e-05	0.00115	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—NRAS—thyroid cancer	1.17e-05	0.00114	CbGpPWpGaD
Valsartan—ALB—Metabolism—TPR—thyroid cancer	1.14e-05	0.00111	CbGpPWpGaD
Valsartan—ALB—Metabolism—PRKAR1A—thyroid cancer	1.12e-05	0.0011	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—BRAF—thyroid cancer	1.1e-05	0.00108	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.01e-05	0.000993	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—KRAS—thyroid cancer	1e-05	0.000985	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—TPR—thyroid cancer	9.29e-06	0.000912	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTGS2—thyroid cancer	9.24e-06	0.000906	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	9.14e-06	0.000897	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—HRAS—thyroid cancer	8.53e-06	0.000837	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	8.53e-06	0.000837	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLC5A5—thyroid cancer	8.5e-06	0.000834	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—AKT1—thyroid cancer	8.3e-06	0.000814	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	8.29e-06	0.000813	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTEN—thyroid cancer	8.06e-06	0.00079	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCND1—thyroid cancer	8e-06	0.000785	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	7.96e-06	0.000781	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPARG—thyroid cancer	7.89e-06	0.000774	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PTEN—thyroid cancer	7.72e-06	0.000757	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—AKT1—thyroid cancer	7.53e-06	0.000739	CbGpPWpGaD
Valsartan—ALB—Metabolism—RXRA—thyroid cancer	7.14e-06	0.0007	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC5A5—thyroid cancer	6.96e-06	0.000682	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	6.95e-06	0.000681	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NRAS—thyroid cancer	6.89e-06	0.000676	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NRAS—thyroid cancer	6.81e-06	0.000668	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	6.52e-06	0.000639	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTGS2—thyroid cancer	6.21e-06	0.000609	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KRAS—thyroid cancer	5.93e-06	0.000582	CbGpPWpGaD
Valsartan—ALB—Hemostasis—KRAS—thyroid cancer	5.86e-06	0.000575	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—RXRA—thyroid cancer	5.85e-06	0.000573	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	5.69e-06	0.000558	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTEN—thyroid cancer	5.41e-06	0.000531	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TP53—thyroid cancer	5.27e-06	0.000517	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TP53—thyroid cancer	5.21e-06	0.000511	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HRAS—thyroid cancer	5.04e-06	0.000494	CbGpPWpGaD
Valsartan—ALB—Hemostasis—HRAS—thyroid cancer	4.98e-06	0.000488	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—AKT1—thyroid cancer	4.64e-06	0.000455	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPARG—thyroid cancer	4.51e-06	0.000442	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AKT1—thyroid cancer	4.45e-06	0.000436	CbGpPWpGaD
Valsartan—ALB—Hemostasis—AKT1—thyroid cancer	4.4e-06	0.000431	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARG—thyroid cancer	3.69e-06	0.000362	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTGS2—thyroid cancer	3.55e-06	0.000348	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AKT1—thyroid cancer	3.12e-06	0.000306	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTEN—thyroid cancer	3.09e-06	0.000303	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTGS2—thyroid cancer	2.9e-06	0.000285	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTEN—thyroid cancer	2.53e-06	0.000248	CbGpPWpGaD
Valsartan—ALB—Metabolism—AKT1—thyroid cancer	1.78e-06	0.000175	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AKT1—thyroid cancer	1.46e-06	0.000143	CbGpPWpGaD
